Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES

Podobne zapisy

• Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
  od: Ferraccioli, Gianfranco, i wsp.
  Wydane: (2016)
• Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis
  od: Alivernini, Stefano, i wsp.
  Wydane: (2019)
• Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression
  od: Bosello, Silvia, i wsp.
  Wydane: (2011)
• Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission
  od: Alivernini, Stefano, i wsp.
  Wydane: (2016)
• Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis
  od: Fedele, Anna Laura, i wsp.
  Wydane: (2014)